An overview of psychedelic + related compounds, including proposed mechanisms of action, physical and physiological risks, and investigational clinical applications. […]
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. “Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?” Journal of Psychopharmacology, Jan 2022.
Agrawal M., Thambi P., Shnayder S. “The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder” Journal of Clinical Oncology, June 2022.
Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
Select Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” Journal of Palliative Medicine, August 2023.
Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.